Common Stock Valuation Ratios (Price Multiples)
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
Pfizer Inc., current price multiples
| Pfizer Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | Health Care | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||
| Current share price (P) | $26.58 | ||||||||||||||||
| No. shares of common stock outstanding | 5,686,267,431 | ||||||||||||||||
| Growth rate (g) | -7.55% | ||||||||||||||||
| Earnings per share (EPS) | $1.37 | ||||||||||||||||
| Next year expected EPS | $1.26 | ||||||||||||||||
| Operating profit per share | $2.50 | ||||||||||||||||
| Sales per share | $11.01 | ||||||||||||||||
| Book value per share (BVPS) | $15.21 | ||||||||||||||||
| Valuation Ratios (Price Multiples) | |||||||||||||||||
| Price to earnings (P/E) | 19.45 | 91.91 | 25.60 | 17.06 | 36.65 | 45.02 | 21.15 | 21.71 | 15.66 | 17.50 | 25.73 | 30.16 | 27.87 | 27.23 | |||
| Price to next year expected earnings | 21.04 | 498.24 | 18.99 | 15.54 | 33.80 | 34.55 | 29.08 | 19.12 | — | 14.88 | 22.70 | 25.70 | 25.49 | 24.81 | |||
| Price to operating profit (P/OP) | 10.61 | 25.77 | 21.74 | 12.03 | 28.24 | 35.33 | 17.96 | 23.02 | 13.47 | 22.04 | 22.27 | 28.57 | 22.04 | 21.27 | |||
| Price to sales (P/S) | 2.42 | 6.35 | 5.62 | 2.50 | 5.39 | 14.26 | 6.22 | 6.18 | 4.40 | 5.50 | 3.87 | 9.93 | 6.00 | 3.21 | |||
| Price to book value (P/BV) | 1.75 | — | 22.80 | 6.51 | 2.52 | 35.02 | 7.93 | 7.14 | 5.43 | 2.52 | 3.23 | 6.39 | 7.42 | 5.85 | |||
Based on: 10-K (reporting date: 2025-12-31).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Pfizer Inc., historical price multiples
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The valuation ratios exhibit considerable fluctuation over the five-year period. Significant shifts are observed across all metrics, suggesting changing investor sentiment and/or underlying business performance impacting market valuation.
- Price to Earnings (P/E)
- The Price to Earnings ratio demonstrates substantial volatility. It decreased from 11.76 in 2021 to a low of 7.58 in 2022, then experienced a dramatic increase to 73.42 in 2023. Subsequently, the ratio declined to 18.42 in 2024 and stabilized slightly at 19.83 in 2025. This pattern indicates a period of undervaluation followed by a significant re-evaluation, and then a return to more moderate levels.
- Price to Operating Profit (P/OP)
- Similar to the P/E ratio, the Price to Operating Profit ratio also shows a marked decrease from 12.74 in 2021 to 6.64 in 2022. A substantial surge to 121.63 occurred in 2023, followed by declines to 11.92 in 2024 and 10.82 in 2025. The correlation with the P/E ratio suggests a strong relationship between earnings and operating profit in influencing market valuation.
- Price to Sales (P/S)
- The Price to Sales ratio exhibits a more stable trend compared to the earnings-based ratios. It decreased from 3.15 in 2021 to 2.35 in 2022, increased to 2.61 in 2023, and then decreased again to 2.32 in 2024, before rising slightly to 2.46 in 2025. This relative stability suggests that revenue is a more consistent driver of valuation than earnings during this period.
- Price to Book Value (P/BV)
- The Price to Book Value ratio consistently declined from 3.35 in 2021 to 1.75 in 2023, indicating a decreasing premium investors were willing to pay for net asset value. The ratio showed limited change in 2024 and 2025, remaining at 1.68 and 1.78 respectively, suggesting a potential stabilization of asset valuation relative to market price.
Overall, the period is characterized by significant shifts in valuation multiples, particularly in 2023, followed by a moderation in subsequent years. The divergence in trends between earnings-based ratios and the Price to Sales ratio suggests a dynamic relationship between profitability, revenue, and market perception.
AI Ask an analyst for more
Price to Earnings (P/E)
Pfizer Inc., historical P/E calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 5,686,267,431 | 5,667,340,414 | 5,646,778,425 | 5,619,074,621 | 5,623,346,471 | |
| Selected Financial Data (US$) | ||||||
| Net income attributable to Pfizer Inc. common shareholders (in millions) | 7,771) | 8,031) | 2,119) | 31,372) | 21,979) | |
| Earnings per share (EPS)2 | 1.37 | 1.42 | 0.38 | 5.58 | 3.91 | |
| Share price1, 3 | 27.10 | 26.10 | 27.55 | 42.30 | 45.96 | |
| Valuation Ratio | ||||||
| P/E ratio4 | 19.83 | 18.42 | 73.42 | 7.58 | 11.76 | |
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| AbbVie Inc. | 94.06 | 79.59 | 63.84 | 22.62 | 22.07 | |
| Amgen Inc. | 25.81 | 38.24 | 23.14 | 19.56 | 21.05 | |
| Bristol-Myers Squibb Co. | 17.30 | — | 12.27 | 23.97 | 20.92 | |
| Danaher Corp. | 40.93 | 38.12 | 39.09 | 25.65 | 29.94 | |
| Eli Lilly & Co. | 47.45 | 77.63 | 135.24 | 50.08 | 40.66 | |
| Gilead Sciences Inc. | 21.54 | 296.57 | 16.17 | 22.68 | 12.36 | |
| Johnson & Johnson | 21.66 | 26.92 | 10.73 | 22.97 | 20.93 | |
| Merck & Co. Inc. | 16.79 | 13.49 | 893.99 | 19.21 | 14.78 | |
| Regeneron Pharmaceuticals Inc. | 18.19 | 17.76 | 25.99 | 19.68 | 8.37 | |
| Thermo Fisher Scientific Inc. | 28.82 | 32.03 | 35.65 | 30.55 | 27.35 | |
| Vertex Pharmaceuticals Inc. | 31.58 | — | 30.42 | 23.02 | 26.55 | |
| P/E Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 28.98 | 45.15 | 32.80 | 20.23 | 19.27 | |
| P/E Ratio, Industry | ||||||
| Health Care | 28.31 | 38.03 | 30.62 | 21.22 | 21.55 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
EPS = Net income attributable to Pfizer Inc. common shareholders ÷ No. shares of common stock outstanding
= 7,771,000,000 ÷ 5,686,267,431 = 1.37
3 Closing price as at the filing date of Pfizer Inc. Annual Report.
4 2025 Calculation
P/E ratio = Share price ÷ EPS
= 27.10 ÷ 1.37 = 19.83
5 Click competitor name to see calculations.
The price to earnings (P/E) ratio exhibited considerable fluctuation over the five-year period. Initial values indicated a relatively moderate valuation, followed by a period of significant volatility and then stabilization. The share price demonstrated a decline from 2021 to 2023, followed by modest recovery in subsequent years. Earnings per share (EPS) experienced a more pronounced pattern of change, with a substantial decrease in 2023 before a partial rebound.
- P/E Ratio Trend
- The P/E ratio began at 11.76 in 2021, decreased to 7.58 in 2022, and then increased dramatically to 73.42 in 2023. This substantial increase in 2023 was primarily driven by a significant decline in earnings per share, while the share price experienced a more moderate decrease. The ratio then decreased to 18.42 in 2024 and remained relatively stable at 19.83 in 2025. This suggests a return towards more typical valuation levels following the outlier reading in 2023.
- Share Price Movement
- The share price decreased from US$45.96 in 2021 to US$42.30 in 2022, representing a modest decline. A more substantial decrease occurred between 2022 and 2023, with the price falling to US$27.55. The share price showed a slight recovery in 2024, reaching US$26.10, and continued to US$27.10 in 2025, indicating a potential stabilization after the prior decline.
- Earnings Per Share (EPS) Fluctuation
- Earnings per share increased from US$3.91 in 2021 to US$5.58 in 2022. However, EPS experienced a dramatic decrease in 2023, falling to US$0.38. A partial recovery was observed in both 2024 and 2025, with EPS reaching US$1.42 and US$1.37 respectively. The volatility in EPS significantly impacted the P/E ratio, particularly in 2023.
The interplay between share price and EPS suggests that investor sentiment and earnings performance have both influenced the valuation. The high P/E ratio in 2023 indicates that investors were willing to pay a substantial premium for each dollar of earnings, likely due to expectations of future earnings recovery. The subsequent moderation of the P/E ratio in 2024 and 2025, coupled with the stabilization of the share price, suggests a more balanced assessment of the company’s prospects.
AI Ask an analyst for more
Price to Operating Profit (P/OP)
Pfizer Inc., historical P/OP calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 5,686,267,431 | 5,667,340,414 | 5,646,778,425 | 5,619,074,621 | 5,623,346,471 | |
| Selected Financial Data (US$) | ||||||
| Operating income (in millions) | 14,244) | 12,411) | 1,279) | 35,789) | 20,290) | |
| Operating profit per share2 | 2.50 | 2.19 | 0.23 | 6.37 | 3.61 | |
| Share price1, 3 | 27.10 | 26.10 | 27.55 | 42.30 | 45.96 | |
| Valuation Ratio | ||||||
| P/OP ratio4 | 10.82 | 11.92 | 121.63 | 6.64 | 12.74 | |
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| AbbVie Inc. | 26.37 | 37.26 | 24.34 | 14.78 | 14.21 | |
| Amgen Inc. | 21.92 | 21.55 | 19.69 | 13.40 | 16.24 | |
| Bristol-Myers Squibb Co. | 12.20 | — | 13.53 | 18.29 | 19.84 | |
| Danaher Corp. | 31.54 | 30.56 | 35.64 | 20.97 | 25.14 | |
| Eli Lilly & Co. | 37.24 | 63.73 | 109.75 | 43.88 | 35.70 | |
| Gilead Sciences Inc. | 18.29 | 85.65 | 12.05 | 14.21 | 7.76 | |
| Johnson & Johnson | 22.95 | 18.20 | 17.78 | 17.62 | 18.68 | |
| Merck & Co. Inc. | 14.44 | 11.60 | 138.56 | 15.55 | 15.39 | |
| Regeneron Pharmaceuticals Inc. | 22.90 | 19.63 | 25.39 | 18.01 | 7.55 | |
| Thermo Fisher Scientific Inc. | 24.94 | 27.65 | 31.16 | 25.30 | 21.07 | |
| Vertex Pharmaceuticals Inc. | 29.92 | — | 28.74 | 17.75 | 22.35 | |
| P/OP Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 22.92 | 31.13 | 32.68 | 15.94 | 16.68 | |
| P/OP Ratio, Industry | ||||||
| Health Care | 22.12 | 26.90 | 27.48 | 16.58 | 18.20 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= 14,244,000,000 ÷ 5,686,267,431 = 2.50
3 Closing price as at the filing date of Pfizer Inc. Annual Report.
4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 27.10 ÷ 2.50 = 10.82
5 Click competitor name to see calculations.
The price to operating profit (P/OP) ratio exhibited significant fluctuations over the five-year period. Initial values decreased, followed by a substantial increase, and then a return towards more moderate levels. This analysis details the observed trends and potential implications.
- Share Price
- The share price demonstrated a decline from US$45.96 in 2021 to US$42.30 in 2022. A more pronounced decrease occurred between 2022 and 2023, falling to US$27.55. The price experienced a further slight reduction in 2024 to US$26.10 before a modest recovery to US$27.10 in 2025.
- Operating Profit per Share
- Operating profit per share increased substantially from US$3.61 in 2021 to US$6.37 in 2022. However, a dramatic decrease was observed in 2023, with operating profit per share falling to US$0.23. A recovery began in 2024, reaching US$2.19, and continued into 2025, with operating profit per share reaching US$2.50.
- Price to Operating Profit (P/OP) Ratio
- In 2021, the P/OP ratio stood at 12.74. It decreased to 6.64 in 2022, coinciding with the increase in operating profit per share. A substantial increase was then recorded in 2023, with the P/OP ratio reaching 121.63, driven by the significant decline in operating profit per share. The ratio decreased considerably in 2024 to 11.92, reflecting the partial recovery in operating profit per share. The P/OP ratio continued to decline slightly in 2025, settling at 10.82.
The volatility in the P/OP ratio is largely attributable to the fluctuations in operating profit per share. The large increase in 2023 suggests that the market significantly re-evaluated the company’s shares relative to its operating profitability during that year. The subsequent decreases in 2024 and 2025, alongside the increasing operating profit per share, indicate a normalization of the valuation multiple. The ratio’s movement suggests a strong sensitivity to changes in reported operating profitability.
AI Ask an analyst for more
Price to Sales (P/S)
Pfizer Inc., historical P/S calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 5,686,267,431 | 5,667,340,414 | 5,646,778,425 | 5,619,074,621 | 5,623,346,471 | |
| Selected Financial Data (US$) | ||||||
| Revenues (in millions) | 62,579) | 63,627) | 59,553) | 101,175) | 82,145) | |
| Sales per share2 | 11.01 | 11.23 | 10.55 | 18.01 | 14.61 | |
| Share price1, 3 | 27.10 | 26.10 | 27.55 | 42.30 | 45.96 | |
| Valuation Ratio | ||||||
| P/S ratio4 | 2.46 | 2.32 | 2.61 | 2.35 | 3.15 | |
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| AbbVie Inc. | 6.50 | 6.04 | 5.72 | 4.61 | 4.53 | |
| Amgen Inc. | 5.66 | 4.88 | 5.78 | 5.17 | 5.10 | |
| Bristol-Myers Squibb Co. | 2.53 | 2.36 | 2.19 | 3.29 | 3.16 | |
| Danaher Corp. | 6.02 | 6.23 | 7.76 | 5.79 | 6.37 | |
| Eli Lilly & Co. | 15.03 | 18.25 | 20.77 | 10.96 | 8.01 | |
| Gilead Sciences Inc. | 6.34 | 4.98 | 3.40 | 3.86 | 2.85 | |
| Johnson & Johnson | 6.16 | 4.26 | 4.43 | 4.34 | 4.66 | |
| Merck & Co. Inc. | 4.71 | 3.60 | 5.43 | 4.71 | 3.96 | |
| Regeneron Pharmaceuticals Inc. | 5.71 | 5.52 | 7.84 | 7.01 | 4.20 | |
| Thermo Fisher Scientific Inc. | 4.34 | 4.73 | 4.99 | 4.73 | 5.39 | |
| Vertex Pharmaceuticals Inc. | 10.40 | 10.78 | 11.16 | 8.56 | 8.21 | |
| P/S Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 6.24 | 5.55 | 5.89 | 4.56 | 4.50 | |
| P/S Ratio, Industry | ||||||
| Health Care | 3.34 | 3.36 | 3.52 | 3.11 | 3.28 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
Sales per share = Revenues ÷ No. shares of common stock outstanding
= 62,579,000,000 ÷ 5,686,267,431 = 11.01
3 Closing price as at the filing date of Pfizer Inc. Annual Report.
4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= 27.10 ÷ 11.01 = 2.46
5 Click competitor name to see calculations.
The price to sales ratio exhibited fluctuations over the five-year period. Initial values decreased, followed by a slight recovery in the most recent year presented.
- Share Price
- The share price demonstrated a decline from US$45.96 in 2021 to US$26.10 in 2024, before experiencing a modest increase to US$27.10 in 2025. This represents an overall decrease of approximately 43.2% from 2021 to 2024, with limited recovery in the final year.
- Sales per Share
- Sales per share increased from US$14.61 in 2021 to US$18.01 in 2022, representing a significant gain. However, this was followed by a substantial decrease to US$10.55 in 2023. Values stabilized somewhat in 2024 and 2025, at US$11.23 and US$11.01 respectively, though remaining below the 2022 peak.
- Price to Sales Ratio
- The price to sales ratio began at 3.15 in 2021, decreasing to 2.35 in 2022. It then rose to 2.61 in 2023, before falling again to 2.32 in 2024. The ratio concluded the period at 2.46 in 2025. The fluctuations in the P/S ratio suggest a dynamic relationship between investor sentiment and the company’s sales performance. The decrease from 2021 to 2022 is consistent with the increase in sales per share, while the subsequent changes reflect the combined impact of share price and sales per share movements.
The interplay between the declining share price and the fluctuating sales per share resulted in a generally decreasing, yet volatile, price to sales ratio over the observed timeframe. The most recent year shows a slight increase in the P/S ratio, potentially indicating a stabilization or modest positive shift in investor perception relative to sales.
AI Ask an analyst for more
Price to Book Value (P/BV)
Pfizer Inc., historical P/BV calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 5,686,267,431 | 5,667,340,414 | 5,646,778,425 | 5,619,074,621 | 5,623,346,471 | |
| Selected Financial Data (US$) | ||||||
| Total Pfizer Inc. shareholders’ equity (in millions) | 86,476) | 88,203) | 89,014) | 95,661) | 77,201) | |
| Book value per share (BVPS)2 | 15.21 | 15.56 | 15.76 | 17.02 | 13.73 | |
| Share price1, 3 | 27.10 | 26.10 | 27.55 | 42.30 | 45.96 | |
| Valuation Ratio | ||||||
| P/BV ratio4 | 1.78 | 1.68 | 1.75 | 2.48 | 3.35 | |
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| AbbVie Inc. | — | 102.40 | 29.97 | 15.52 | 16.53 | |
| Amgen Inc. | 22.99 | 26.61 | 24.94 | 35.01 | 18.51 | |
| Bristol-Myers Squibb Co. | 6.61 | 6.98 | 3.35 | 4.88 | 4.07 | |
| Danaher Corp. | 2.82 | 3.00 | 3.47 | 3.64 | 4.16 | |
| Eli Lilly & Co. | 36.91 | 57.93 | 65.80 | 29.36 | 25.28 | |
| Gilead Sciences Inc. | 8.07 | 7.36 | 4.01 | 4.90 | 3.65 | |
| Johnson & Johnson | 7.12 | 5.30 | 5.48 | 5.37 | 5.90 | |
| Merck & Co. Inc. | 5.82 | 4.99 | 8.68 | 6.07 | 5.05 | |
| Regeneron Pharmaceuticals Inc. | 2.62 | 2.67 | 3.96 | 3.77 | 3.60 | |
| Thermo Fisher Scientific Inc. | 3.62 | 4.09 | 4.57 | 4.83 | 5.18 | |
| Vertex Pharmaceuticals Inc. | 6.69 | 7.24 | 6.26 | 5.50 | 6.16 | |
| P/BV Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 7.72 | 7.03 | 6.77 | 5.66 | 5.72 | |
| P/BV Ratio, Industry | ||||||
| Health Care | 6.08 | 5.99 | 5.94 | 5.26 | 5.48 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
BVPS = Total Pfizer Inc. shareholders’ equity ÷ No. shares of common stock outstanding
= 86,476,000,000 ÷ 5,686,267,431 = 15.21
3 Closing price as at the filing date of Pfizer Inc. Annual Report.
4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= 27.10 ÷ 15.21 = 1.78
5 Click competitor name to see calculations.
The price to book value (P/BV) ratio exhibited a declining trend from 2021 to 2023, followed by a period of relative stabilization. The share price decreased over the observed period, while the book value per share experienced fluctuations. These movements collectively influenced the P/BV ratio.
- Price to Book Value (P/BV) Trend
- The P/BV ratio decreased from 3.35 in 2021 to 2.48 in 2022, representing a substantial decline. This downward trend continued into 2023, with the ratio falling to 1.75. From 2023 to 2025, the P/BV ratio remained relatively stable, fluctuating between 1.68 and 1.78. This suggests a potential leveling off in the market’s valuation of the company’s net assets.
- Share Price Movement
- The share price experienced a consistent decline from US$45.96 in 2021 to US$26.10 in 2024. A slight increase to US$27.10 was observed in 2025, but the price remained significantly lower than its 2021 level. This decrease in share price contributed to the overall reduction in the P/BV ratio.
- Book Value per Share (BVPS) Fluctuation
- The book value per share increased from US$13.73 in 2021 to US$17.02 in 2022, before decreasing to US$15.76 in 2023. Further declines were noted in 2024 (US$15.56) and 2025 (US$15.21). While the share price decreased more rapidly, the decreasing BVPS partially offset this effect on the P/BV ratio.
The combined effect of a declining share price and fluctuating book value per share resulted in a significant decrease in the P/BV ratio over the period. The stabilization of the P/BV ratio in the later years suggests that the market’s assessment of the company’s net asset value, relative to its share price, has reached a new equilibrium.
AI Ask an analyst for more